Quantcast

Latest PDL BioPharma Inc. Stories

2014-10-08 08:27:55

INCLINE VILLAGE, Nev., Oct. 8, 2014 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL" or "the Company") (NASDAQ: PDLI), today announced the appointment of PricewaterhouseCoopers LLP ("PwC") as its independent registered public accounting firm. PwC will commence work immediately, beginning with their review of our financial results for the three and nine months ending September 30, 2014. PwC is the United States member firm of a leading professional services global network that delivers...

2014-10-06 08:27:58

INCLINE VILLAGE, Nev., Oct. 6, 2014 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI), today announced two enhancements to the company's management team. Danny Hart, who has served in the position of deputy general counsel, assistant secretary and corporate counsel since 2010, has been appointed to the position of vice president, business development. Nathan Kryszak, who joins the company from the international law firm, White & Case LLP, has been appointed to the...

2014-09-23 08:31:57

INCLINE VILLAGE, Nev., Sept. 23, 2014 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI), has been informed of a class action lawsuit filed against the company that alleges violations of federal securities laws. The company disputes the allegations in the complaint and will vigorously defend this lawsuit. "We believe that any claims alleging violations of securities laws are without merit and we intend to vigorously defend our position," stated John P. McLaughlin, president and...

2014-09-17 20:22:11

INCLINE VILLAGE, Nev., Sept. 17, 2014 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) was orally notified by its independent registered accounting firm, Ernst & Young LLP ("EY") that it was resigning effective September 11, 2014. The resignation was confirmed in a letter delivered to the Company on September 15, 2014 and reported in PDL's Form 8-K filed on September 16, 2014. PDL has issued the following statement in response to the announcement: "We have received a...

2014-09-17 16:27:03

NEW YORK, Sept. 17, 2014 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of PDL BioPharma, Inc. ("PDL BioPharma" or the "Company") (NASDAQ: PDLI). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. 237. The investigation concerns whether PDL BioPharma and certain of its officers and/or directors have violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934. On September 17, 2014,...

2014-09-15 12:28:13

INCLINE VILLAGE, Nev., Sept. 15, 2014 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that it has paid the September 12, 2014, regular quarterly dividend payment of $0.15 per share to all stockholders owning shares of PDL as of September 5, 2014, the record date. About PDL BioPharma PDL BioPharma manages a portfolio of patents and royalty assets, consisting primarily of its Queen et al. antibody humanization patents and license agreements with various...

2014-09-09 16:26:30

INCLINE VILLAGE, Nev., Sept. 9, 2014 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced revenue guidance for the third quarter ending September 30, 2014, of approximately $165 million, as compared with actual revenue of $100.2 million for the third quarter of 2013, an approximate 65 percent increase. The forecasted revenues for the third quarter of 2014 include royalty payments from PDL's licensees to the Queen et al. patents, net royalty payments from acquired royalty...

2014-09-04 16:27:33

INCLINE VILLAGE, Nev., Sept. 4, 2014 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that the adjusted conversion rate for the: -- 3.75% Convertible Senior Notes due May 1, 2015 (May 2015 Notes), is 167.9812 shares of common stock per $1,000 principal amount or approximately $5.95 per share, effective September 3, 2014? and -- 2.875% Series 2012 Convertible Senior Notes due February 15, 2015 (Series 2012 Notes), is 191.671 shares of...

2014-08-25 23:01:57

PDL BioPharma President & CEO John McLaughlin to step down. Alachua, FL (PRWEB) August 25, 2014 AxoGen, Inc. (NASDAQ: AXGN), a leading medical technology company focused on the peripheral nerve repair market, reported today that John McLaughlin, President and Chief Executive Officer of PDL BioPharma, Inc. has resigned from AxoGen’s Board of Directors. Mr. McLaughlin joined AxoGen’s Board in 2012 as part of the Revenue Interest Purchase Agreement between AxoGen and PDL. At this...

2014-08-18 16:27:53

-Revenues Increased 23 Percent Year to Date- INCLINE VILLAGE, Nev., Aug. 18, 2014 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today reported financial results for the second quarter and six months ended June 30, 2014. Total revenues for the second quarter of 2014 increased approximately 10 percent to $162.8 million from $148.5 million in the second quarter of 2013. Revenues for the second quarter of 2014 include royalty payments from PDL's licensees to the Queen et...


Word of the Day
negawatt
  • A unit of saved energy.
Coined by Amory Lovins, chairman of the Rocky Mountain Institute as a contraction of negative watt on the model of similar compounds like megawatt.